Results 211 to 220 of about 113,104 (262)

Single-dose rituximab as induction therapy in adult IgA vasculitis with rapidly progressive glomerulonephritis: a case report with peripheral blood CD19⁺ B-cell monitoring. [PDF]

CEN Case Rep
Kyoda N, Ago R, Masuzawa N, Yanamoto M, Aizawa M, Masaki T.   +5 more
europepmc   +1 more source

Emerging Applications of CAR-T Cell Therapy in Overcoming Resistance and Expanding Targets in Hematologic Malignancies: Insights from Recent Research. [PDF]

Curr Treat Options Oncol
Alipourfard I, Shafaghat Z, Saharkhiz S, Farani MR, Bakhtiyari S.   +4 more
europepmc   +1 more source

A Rare Case of Concurrent Chronic Lymphocytic Leukemia and Therapy-Unrelated Acute Myeloid Leukemia That Evolved From Myelodysplastic Neoplasm. [PDF]

Cureus
Bansil S, Lai SY, Lo AE, Dietz R, Reed JP.   +4 more
europepmc   +1 more source

Robust production of heavy-chain-only antibodies in mice by CRISPR/Cas mediated <i>in situ</i> modification of <i>IgH</i> locus. [PDF]

Natl Sci Rev
Wang W, Zheng S, Xiang G, Feng T, Peng Y, Wu Y, Du X, Zhu P, Ru Y, Zhang J, Wu S, Han H, Huang T, Cao G, Zheng H, Zhao Y, Wang H, Zhang R.   +17 more
europepmc   +1 more source

Complementary efficacy of CD127-directed immunotherapy with lusvertikimab and ABL-targeting tyrosine kinase inhibitors in preclinical ABL-class-fusion-positive B-ALL. [PDF]

Hemasphere
Pinkle D, Cornils M, Dietterle A, Laqua A, Kurschies M, Heymann J, Funke E, Fanter P, Gupta DD, Reimer C, Mahachi DT, Gehlert CL, Winterberg D, Vossen-Gajcy M, Müller X, Balow G, Iben K, Barz M, Bastian L, Baldus C, Kowol M, Kikvadze S, Wurm AA, Logvinova E, Vokuhl C, Schmid JP, Jeremias I, Klausz K, Peipp M, Schrappe M, Baccelli I, Poirier N, Brüggemann M, Cario G, Schewe DM, Lenk L.   +35 more
europepmc   +1 more source

Safety profile of chimeric antigen receptor T‐cell therapy in relapsed/refractory multiple myeloma: A systematic review and meta‐analysis of proportions from clinical trials

British Journal of Haematology, EarlyView.
Charalampos Filippatos, Ioannis Ntanasis‐Stathopoulos, Areti Voulomenou, Panagiotis Malandrakis, Efstathios Kastritis, Maria Gavriatopoulou, Meletios‐Athanasios Dimopoulos, Evangelos Terpos   +7 more
wiley   +1 more source

Case Report: Compromised response of memory-formed bystander T cells after CD19 CAR-T cell therapy following CD20 bispecific antibody therapy. [PDF]

Front Immunol
Masuda Y, Kato J, Konishi T, Honda T, Maruta M, Kawasaki N, Matsumoto M, Oka K, Mori K, Nabe S, Miyazaki Y, Matsubara E, Urata S, Kinnami S, Doi Y, Takasuka Y, Yamanouchi J, Ochi T, Takenaka K.   +18 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Retargeting CD19 Chimeric Antigen Receptor T Cells via Engineered CD19-Fusion Proteins

Molecular Pharmaceutics, 2019
CD19-targeted chimeric antigen receptor (CAR) T-cells (CAR19s) show remarkable efficacy in the treatment of relapsed/refractory acute lymphocytic leukemia and Non-Hodgkin's lymphoma. However, the use of CAR T-cell therapy against CD19-negative hematological cancers and solid tumors has been challenging.
Paul Rennert, Justin R Klesmith, Benjamin Hackel   +2 more
exaly   +3 more sources

Characterization of porcine CD19 and anti-CD19 monoclonal antibodies

Molecular Immunology, 2004
CD19 is an important pan B cell marker and co-stimulatory protein in humans and mice. Efforts to further characterize B cell ontogeny in swine have been hampered by the lack of monoclonal antibodies (mAb) to valuable surface markers like Vpre-B, CD19, CD34 and CD43.
Jishan, Sun, Jiri, Sinkora, Nancy, Wertz, Alena, Moravkova, J E, Butler   +4 more
openaire   +2 more sources

Deficiencies in the CD19 complex

Clinical Immunology, 2018
Signaling via the CD19-complex, consisting of CD19, CD81, CD21 and CD225, is critically important for B-cell development, differentiation and maturation. In this complex, each protein has its own distinct function. Over the past decade, 15 patients with antibody deficiency due to deficiencies in the CD19-complex have been described. These patients have
Marjolein W.J. Wentink, Menno C. van Zelm, Jacques J.M. van Dongen, Klaus Warnatz, Mirjam van der Burg   +4 more
openaire   +5 more sources